RARE Q1 Loss Wider Than Expected, Sales Down Y/Y on Seasonal Effect

Ultragenyx reported a wider-than-expected Q1 loss, pressured by lower Crysvita sales due to seasonal effects. Revenue growth in Evkeeza and Dojolvi partially offset the decline, but the overall earnings read-through is negative and likely to weigh modestly on the stock.

Analysis

Ultragenyx reported a wider-than-expected Q1 loss, pressured by lower Crysvita sales due to seasonal effects. Revenue growth in Evkeeza and Dojolvi partially offset the decline, but the overall earnings read-through is negative and likely to weigh modestly on the stock.